Announcements
U.S. Food and Drug Administration (FDA) Advisory
November 15, 2017: Febuxostat (Brand Name Uloric): FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of heart-related death with febuxostat (Uloric) compared to another gout medicine called allopurinol. FDA required the Uloric drug manufacturer, Takeda Pharmaceuticals, to conduct this safety study when the medicine was approved in 2009. Once the final results from the manufacturer are received, FDA will conduct a comprehensive review and will update the public with any new information.
G-I-N NA Co-sponsored Conference
Evidence-Based Clinical Practice Guidelines, Development and Implementation in Mexico, International Forum
When: November 30, 2017 - December 1, 2017
Where: Universidad Nacional Autonoma de Mexico, Postgraduate Unit Auditorium, Mexico
Admission Information & Registration: Contact Jose Luis Mayorga Butron, MD, MSc
View the preliminary program.
When: November 30, 2017 - December 1, 2017
Where: Universidad Nacional Autonoma de Mexico, Postgraduate Unit Auditorium, Mexico
Admission Information & Registration: Contact Jose Luis Mayorga Butron, MD, MSc
View the preliminary program.
Health Awareness Topics: November 2017
- American Diabetes Month (see related guidelines)
- COPD Awareness Month (see related guidelines)
- Diabetic Eye Disease Month (see related guidelines)
- Lung Cancer Awareness Month (see related guidelines)
- National Alzheimer's Disease Awareness Month (see related guidelines)
- Stomach Cancer Awareness Month (see related guidelines)
How to Participate
Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.
No hay comentarios:
Publicar un comentario